Last edition
News about "PAPILLON trial"
J&J's RYBREVANT Plus Chemotherapy Delivers Nearly 3-Year Survival in EGFR Exon 20 NSCLC
J&J’s RYBREVANT (amivantamab) plus chemotherapy delivers a median Overall Survival of 34.3 months in EGFR exon 20 insertion mutation-positive Non-Small Cell Lung Cancer (NSCLC).
PAPILLON Trial | 14/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members